Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct pulmonary vascular disease caused by chronic obstruction of major pulmonary arteries that is amenable to cure by pulmonary ...

Jolie Lizana is a Louisiana woman with a strong sense of hospitality and humor. She was diagnosed 12 years ago with systemic ...

New columnist Jolie Lizana shares her harrowing journey to a pulmonary hypertension diagnosis and finding purpose in advocacy ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price ...

Eli Lilly & Co. has divulged relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of diabetes, stroke, atherosclerosis, pulmonary hypertension, chronic obstructive ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The pulmonary arterial hypertension market is expected to reach USD 2,080.7 million by 2025 and is expected to steadily grow at a CAGR of 2.3% to reach USD 2,612.0 million by 2035.

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Body weight significantly influenced right heart function and survival in pulmonary arterial hypertension, with both extremes ...